By Fineline Cube 
Suzhou Forlong Biotechnology Co., Ltd. today revealed a strategic partnership with Shanghai Henlius Biotech, Inc. (HKG: 2696) to jointly develop a next‑generation tumor immunotherapy based on engineered cytokines. Under the agreement, Forlong Biotech will fuse a bespoke engineered cytokine to a monoclonal antibody directed at Henlius‑specified antigens, creating a novel therapeutic aimed at enhancing anti‑tumor immunity.
Collaboration Highlights
- Technology Focus – Site‑specific fusion of engineered cytokines with monoclonal antibodies for precise tumor targeting.
- Financial Structure – Forlong Biotech to receive an upfront R&D payment, milestone payments at key developmental milestones, and additional licensing revenues upon achievement of preset target milestones.
- Strategic Benefit – The alliance combines Forlong’s advanced cytokine platform with Henlius’s oncology expertise to accelerate the pipeline of innovative cancer immunotherapies.
Business Implications
- Rapid Development Pathway – The engineered cytokine‑antibody platform promises quicker transition from discovery to clinical candidates compared to conventional biologics.
- Market Opportunity – Targeting high‑value tumor antigens aligns with the growing demand for personalized, immune‑based cancer treatments.
- Risk Mitigation – Structured milestone payments align incentives and share development risk between the two collaborators.
Forward‑Looking Statements
Both companies acknowledge that these forward‑looking statements are subject to risks and uncertainties; actual results may differ materially.-Fineline Info & Tech